Literature DB >> 26971984

[Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH].

Alejandro Forner1, María Reig1, María Varela2, Marta Burrel3, Jaime Feliu4, Javier Briceño5, Javier Sastre6, Luis Martí-Bonmati7, Josep María Llovet8, José Ignacio Bilbao9, Bruno Sangro10, Fernando Pardo11, Carmen Ayuso3, Concepció Bru3, Josep Tabernero12, Jordi Bruix13.   

Abstract

Hepatocellular carcinoma is the most common primary malignancy of the liver and one of the most frequent causes of death in patients with liver cirrhosis. Simultaneously with the recognition of the clinical relevance of this neoplasm, in recent years there have been important developments in the diagnosis, staging and treatment of HCC. Consequently, the Asociación Española para el Estudio del Hígado has driven the need to update clinical practice guidelines, continuing to invite all the societies involved in the diagnosis and treatment of this disease to participate in the drafting and approval of the document (Sociedad Española de Trasplante Hepático, Sociedad Española de Radiología Médica, Sociedad Española de Radiología Vascular e Intervencionista y Sociedad Española de Oncología Médica). The clinical practice guidelines published in 2009 accepted as Clinical Practice Guidelines of the National Health System has been taken as reference document, incorporating the most important advances that have been made in recent years. The scientific evidence for the treatment of HCC has been evaluated according to the recommendations of the National Cancer Institute (www.cancer.gov) and the strength of recommendation is based on the GRADE system.
Copyright © 2016 Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Carcinoma hepatocelular; Cirrosis hepática; Hepatocellular carcinoma; Hígado; Liver; Liver cirrhosis

Mesh:

Year:  2016        PMID: 26971984     DOI: 10.1016/j.medcli.2016.01.028

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  7 in total

Review 1.  2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.

Authors:  Ashish Kumar; Subrat K Acharya; Shivaram P Singh; Anil Arora; Radha K Dhiman; Rakesh Aggarwal; Anil C Anand; Prashant Bhangui; Yogesh K Chawla; Siddhartha Datta Gupta; Vinod K Dixit; Ajay Duseja; Naveen Kalra; Premashish Kar; Suyash S Kulkarni; Rakesh Kumar; Manoj Kumar; Ram Madhavan; V G Mohan Prasad; Amar Mukund; Aabha Nagral; Dipanjan Panda; Shashi B Paul; Padaki N Rao; Mohamed Rela; Manoj K Sahu; Vivek A Saraswat; Samir R Shah; Praveen Sharma; Sunil Taneja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2019-09-23

Review 2.  Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies.

Authors:  N Merchante; M Rodríguez-Fernández; J A Pineda
Journal:  Curr HIV/AIDS Rep       Date:  2020-02       Impact factor: 5.071

3.  Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study.

Authors:  Víctor Molina; Jaime Sampson-Dávila; Joana Ferrer; Constantino Fondevila; Rafael Díaz Del Gobbo; David Calatayud; Jordi Bruix; Juan Carlos García-Valdecasas; Josep Fuster
Journal:  Surg Endosc       Date:  2017-12-07       Impact factor: 4.584

4.  TIPE‑2 suppresses growth and aggressiveness of hepatocellular carcinoma cells through downregulation of the phosphoinositide 3‑kinase/AKT signaling pathway.

Authors:  Lin Wang; Chen Chen; Shuzhi Feng; Jianli Tian
Journal:  Mol Med Rep       Date:  2018-03-20       Impact factor: 2.952

5.  Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR.

Authors:  Susana Llerena; Nuria García-Díaz; Soraya Curiel-Olmo; Antonio Agraz-Doblas; Agustín García-Blanco; Helena Pisonero; María Varela; Miguel Santibáñez; Carmen Almaraz; Laura Cereceda; Nerea Martínez; María Teresa Arias-Loste; Ángela Puente; Luis Martín-Ramos; Carlos Rodríguez de Lope; Federico Castillo-Suescun; Carmen Cagigas-Fernandez; Pablo Isidro; Carlos Lopez-López; Marcos Lopez-Hoyos; Javier Llorca; Jesús Agüero; Benedicto Crespo-Facorro; Ignacio Varela; Miguel Ángel Piris; Javier Crespo; José Pedro Vaqué
Journal:  Oncotarget       Date:  2018-07-20

6.  Effect of isoform-specific HIF-1α and HIF-2α antisense oligonucleotides on tumorigenesis, inflammation and fibrosis in a hepatocellular carcinoma mouse model.

Authors:  Bart Vanderborght; Kevin De Muynck; Sander Lefere; Anja Geerts; Helena Degroote; Xavier Verhelst; Hans Van Vlierberghe; Lindsey Devisscher
Journal:  Oncotarget       Date:  2020-12-01

7.  Exhaled volatile organic compounds for diagnosis of hepatocellular carcinoma.

Authors:  Thanikan Sukaram; Rossarin Tansawat; Terapap Apiparakoon; Thodsawit Tiyarattanachai; Sanparith Marukatat; Rungsun Rerknimitr; Roongruedee Chaiteerakij
Journal:  Sci Rep       Date:  2022-03-29       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.